<DOC>
	<DOC>NCT01433328</DOC>
	<brief_summary>Treprostinil subcutaneous (under the skin) infusion is a very good medication for treating pulmonary arterial hypertension but infusion site pain may be very severe in some patients. The investigators plan to treat patients receiving treprostinil with a subcutaneous infusion of lidocaine (a local anesthestic) to treat the pain.</brief_summary>
	<brief_title>Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>PAH Treprostinil treatment for at least 3 months Severe infusion site pain Pregnancy/breastfeeding Decompensated heart failure Chronic liver disease Abnormal electrolytes Heart block (2/3 degree), sinoatrial block, idioventricular rhythm Systolic systemic BP &lt;90mmHg Bradycardia HR &lt;55 Adverse reaction to lidocaine or other amide local anesthestic Interacting medications (antiarrhythmics, CYP1A2 inhibitors)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Remodulin</keyword>
	<keyword>Treprostinil</keyword>
</DOC>